Sapporo Clinical Laboratory (TSE:9776) Long-Term Debt: 円1,264 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:9776 Sapporo Clinical Laboratory Inc TSE:9776
43 GF Score
Price 円1,960.00
GF Value 円1,041.47
! 4 Warning Signs
View Full Analysis

What is Sapporo Clinical Laboratory Long-Term Debt?

Sapporo Clinical Laboratory TSE:9776 43 Long-Term Debt is 円1,264 Mil as of Sep. 2025. GuruFocus rates TSE:9776 with a GF Score™ of 43/100 and a GF Value™ of 円1,041.47. The stock has 4 warning signs investors should review.

Sapporo Clinical Laboratory's Long-Term Debt for the quarter that ended in Sep. 2025 was 円1,264 Mil.

Sapporo Clinical Laboratory's quarterly Long-Term Debt declined from Sep. 2024 (円1,398 Mil) to Mar. 2025 (円1,331 Mil) and declined from Mar. 2025 (円1,331 Mil) to Sep. 2025 (円1,264 Mil).

Sapporo Clinical Laboratory's annual Long-Term Debt declined from Mar. 2023 (円1,599 Mil) to Mar. 2024 (円1,465 Mil) and declined from Mar. 2024 (円1,465 Mil) to Mar. 2025 (円1,331 Mil).

Sapporo Clinical Laboratory  (TSE:9776) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Sapporo Clinical Laboratory Long-Term Debt Related Terms

Sapporo Clinical Laboratory Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Sapporo Clinical Laboratory's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sapporo Clinical Laboratory Long-Term Debt Chart

Sapporo Clinical Laboratory Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,866.01 1,732.32 1,598.63 1,464.94 1,331.25

Sapporo Clinical Laboratory Semi-Annual Data
Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,531.78 1,464.94 1,398.09 1,331.25 1,264.40
TSE:9776
43GF Score
Sapporo Clinical Laboratory Inc TSE:9776
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of 円1,264 Mil mean?
Sapporo Clinical Laboratory (TSE:9776) has a Long-Term Debt of 円1,264 Mil as of Sep. 2025.
Is Sapporo Clinical Laboratory's Long-Term Debt too high?
Sapporo Clinical Laboratory's current Long-Term Debt is 円1,264 Mil. Overall, Sapporo Clinical Laboratory has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Sapporo Clinical Laboratory's Long-Term Debt compare to competitors?
Sapporo Clinical Laboratory's Long-Term Debt of 円1,264 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Healthcare Providers & Services company?
A good Long-Term Debt depends on the Healthcare Providers & Services industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Sapporo Clinical Laboratory's current Long-Term Debt is 円1,264 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sapporo Clinical Laboratory stock overvalued right now?
Sapporo Clinical Laboratory (TSE:9776) has a current Long-Term Debt of 円1,264 Mil. The stock's GF Value™ is 円1,041.47, compared to a current price of 円1,960.00 — trading 88.2% above its estimated fair value. The current Long-Term Debt is 円1,264 Mil. Sapporo Clinical Laboratory's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Sapporo Clinical Laboratory (TSE:9776), the current Long-Term Debt is 円1,264 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sapporo Clinical Laboratory (TSE:9776) Overvalued in 2026?

Based on GuruFocus' analysis, Sapporo Clinical Laboratory stock appears to be overvalued. The current stock price of 円1,960.00 is trading 88.2% above its estimated GF Value™ of 円1,041.47.

Key valuation signals for TSE:9776:

  • Long-Term Debt: 円1,264 Mil
  • GF Value™: 円1,041.47 vs. price of 円1,960.00 (88.2% above fair value)
  • GF Score™: 43/100 with 4 warning signs

No single metric tells the full story. See the TSE:9776 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sapporo Clinical Laboratory Business Description

Address 18-9-1 Nishi Kita-Gojo, Chuo-ku Sapporo, Hokkaido, Sapporo, JPN, 060 0005
Sapporo Clinical Laboratory Inc. is a Japan based company engaged in offering clinical testing services. Its portfolio of services covers clinical examination, pathological examination, dispensing pharmacy, food hygiene environmental test, and radiation management. It is also engaged in the development of an integrated system for clinical testing.
43GF Score

Get the complete analysis for TSE:9776

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,960.00
Price
円1,041.47
GF Value